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Abstract
Background: Depression is experienced as a persistent low mood or anhedonia accompanied by behavioural and cognitive
disturbances which impair day to day functioning. However, the diagnosis is largely based on self-reported symptoms, and
there are no neurobiological markers to guide the choice of treatment. In the present study, we examined the prognostic
and diagnostic potential of the structural neural correlates of depression.
Methodology and Principal Findings: Subjects were 37 patients with major depressive disorder (mean age 43.2 years),
medication-free, in an acute depressive episode, and 37 healthy individuals. Following the MRI scan, 30 patients underwent
treatment with the antidepressant medication fluoxetine or cognitive behavioural therapy (CBT). Of the patients who
subsequently achieved clinical remission with antidepressant medication, the whole brain structural neuroanatomy
predicted 88.9% of the clinical response, prior to the initiation of treatment (88.9% patients in clinical remission (sensitivity)
and 88.9% patients with residual symptoms (specificity), p= 0.01). Accuracy of the structural neuroanatomy as a diagnostic
marker though was 67.6% (64.9% patients (sensitivity) and 70.3% healthy individuals (specificity), p= 0.027).
Conclusions and Significance: The structural neuroanatomy of depression shows high predictive potential for clinical
response to antidepressant medication, while its diagnostic potential is more limited. The present findings provide initial
steps towards the development of neurobiological prognostic markers for depression.
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Introduction
While neurodegenerative disorders such as Alzheimer’s disease
have diagnostic structural and functional brain abnormalities [1],
the diagnosis of other psychiatric disorders is based entirely on
clinical signs and symptoms. Investigation of objective, neurobi-
ological markers would support diagnostic systems and treatment
decisions. The potential of a biomarker though depends on its
predictive power at the level of the individual.
We found that the functional neuroimaging correlates of core
affective processing have significant potential as a diagnostic
marker for depression. The functional neuroanatomy of implicit
processing of sad facial expressions showed an accuracy of 86% in
identifying individuals in an acute depressive episode [2], while
verbal working memory had a more limited but still significant
diagnostic accuracy [3]. Sad facial expressions are socially
relevant, emotional cues which engage a distributed network of
regions [4] that show an abnormal response during an acute
depressive episode [5–6]. Moreover, the neural pattern to sad faces
also demonstrated high prognostic potential for the prediction of
clinical response to cognitive behavioural therapy (CBT) [7].
In the present study, we investigated the structural neuroanat-
omy of depression as a prognostic and diagnostic marker for
depression. As a marker of clinical response in depression, we
found that regional volumes in the anterior cingulate, temporal
cortices and basal ganglia were correlated with the rate of clinical
improvement [8]. The analysis though was limited to the original
sample, and the predictive response in novel data was not
explicitly examined. In schizophrenia, Davatzikos et al. [9]
reported a diagnostic accuracy of 81% from whole brain structural
neuroimaging features. However, global cerebral volume in major
depression is comparable to healthy individuals, in contrast to
schizophrenia [10]. Instead, structural deficits in depression
appear to be more localised within a distributed pattern, which
include the hippocampus [11], subgenual anterior cingulate [12–
13], orbitofrontal and middle frontal cortices [14], and basal
ganglia [reviewed in: 10,15].
We expected the structural correlates of depression to show
significant predictive potential for treatment with antidepressant
medication, implicating regions which would include the anterior
cingulate cortex, while the predictive potential for treatment with
CBT was less clear. As a potential diagnostic marker, we
expected a lower accuracy than observed in schizophrenia [8],
which would encompass a distributed network including the
anterior cingulate and prefrontal regions, hippocampus, and
basal ganglia.
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Results
The structural neuroanatomy of acutely depressed patients,
before the initiation of treatment, correctly predicted clinical
remission to treatment with the antidepressant medication fluoxe-
tine with an accuracy of 88.9% (88.9% of patients in clinical
remission (sensitivity) and 88.9% patients with residual symptoms
(specificity), p=0.01). Clinical remission was predicted by greater
grey matter density in the right rostral anterior cingulate cortex (BA
32), left posterior cingulate cortex (BA 31), left middle frontal gyrus
(BA 6), and right occipital cortex (BA 19) (Figure 1). Regions which
predicted residual symptoms were the orbitofrontal cortices
bilaterally (BA 11), right superior frontal cortex (BA 10) and left
hippocampus. The structural neuroanatomy did not show a
significant prediction of clinical remission to CBT.
As a diagnostic marker, the accuracy was 67.6% from whole
brain structural neuroanatomy (64.9% patients with depression
(sensitivity) and 70.3% healthy individuals (specificity), p=0.027).
Decreased grey matter density in the following regions showed the
highest contribution to the diagnosis of depression: right subgenual
anterior cingulate (BA 25), medial frontal gyrus (BA 11), superior
temporal cortex (BA 22), precuneus (BA 7), hippocampus and
thalamus, as well as in the left inferior parietal cortex (BA 40),
occipital (BA 19) cortex, and cerebellum. No regions of increased
grey matter in depressed patients relative to healthy individuals
contributed to the diagnosis.
Regions which contributed to the prediction of treatment
response were distinct from those relevant for diagnosis as there
was no overlap anywhere in the brain between their respective
brain patterns.
Discussion
Whole brain structural neural correlates of depression identified
89% of patients who subsequently had a full clinical response to
the antidepressant medication fluoxetine. The structural neuro-
anatomy of depression has significant potential as a prognostic
marker of treatment response with antidepressant medication. In
contrast, the structural neuroanatomy showed limited potential as
a diagnostic measure for depression.
The findings support functional [5,16–18] and structural [8]
neuroimaging studies implicating the anterior cingulate cortex as a
marker of clinical response to antidepressant medication, but also
identified a more widespread network which included the
posterior cingulate. The anterior and posterior cingulate cortices
are strongly interconnected [19], and their functions are
complementary with the anterior cingulate subserving executive
functions linked to emotional and autonomic responses while the
posterior cingulate has a more evaluative role that is postulated to
direct activity in the anterior cingulate [20]. The data also point to
a more widespread network of regions which are predictive of
clinical response, including the hippocampus which may reflect
stress-induced neuroplastic changes [21–24]. In particular, the
present study suggests that grey matter density in a set of regions
predicts how well an individual patient will respond to antidepres-
sant treatment. In contrast, whole brain functional responses to
sad faces showed high predictive potential to CBT treatment [6].
Regions important for individual diagnosis have been featured
within the cortico-striato-pallido-thalamic loops, which include the
medial and orbital prefrontal cortices, amygdala, hippocampus,
medial thalamus, and striatum [25], and cortico-cortical circuits
Figure 1. Sagittal cross-sectional view of regions pertinent for diagnosis and prediction of treatment response in depression. In the
top panel, sagittal views are presented which show medial regions of decreased grey matter density which contributed to the diagnosis of
depression (coloured in green) in the right subgenual anterior cingulate (BA 25) and precuneus (BA 7). No regions of increased grey matter in patients
with depression relative to healthy individuals contributed to the diagnosis. In the lower panel, increased grey matter density in the anterior and
posterior cingulate cortices (red) increased the probability of clinical remission to treatment with the antidepressant medication fluoxetine. Greater
density in the orbitofrontal cortex (blue) increased the odds of residual symptoms of depression following antidepressant medication. Regions
depicted were selected as relevant to the classification of patients as achieving remission or non-remission clinical status following fluoxetine
treatment by every cross-validated support vector machine classification model. Sagittal views are presented in MNI space at z =24, 10, 12 and 14.
doi:10.1371/journal.pone.0006353.g001
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from the medial prefrontal cortex connecting the parahippocampus,
posterior cingulate and superior temporal cortices [26]. In
depression, volumetric and cellular deficits have most consistently
been identified in the hippocampus [11], but as well in the anterior
[12] and posterior cingulate [13], orbitofrontal [14], lateral temporal
and occipital cortices [23,27], and amygdala [28]. However, the
structural neuroanatomy only showed limited potential for diagno-
sis, suggesting that structural abnormalities in depression are slight in
contrast to other psychiatric disorders, such as schizophrenia [9].
Instead, functional brain activity to sad facial expressions may be a
more accurate diagnostic marker of depression [2].
A limitation of the present study was the small sample sizes in
the prediction of clinical response, which may not have provided
sufficient power to find an effect for CBT. Although such negative
findings should be treated with caution, one interpretation would
be that structural brain regions predictive of response to CBT,
should they exist, may be more subtle than those predictive of
fluoxetine response. Yet, as the sample for the CBT treatment
group was sufficient to detect a predictive potential of functional
MRI [7], it is possible that if structural effects exist, they might be
more subtle than functional ones. Another limitation was that the
pharmacological treatment was a single medication from the class
of serotonergic reuptake inhibitors. The predictive potential for
other antidepressant medications and from other classes requires
further investigation. Moreover, the specificity of the predictive
marker is somewhat equivocal as there was no placebo treatment
arm. All patients in the present study were medication-free and
suffering from an acute depressive episode at the time of the MRI
scan. The generalisability of our findings to patients with more
chronic forms of depression and the effects of medication from
different classes, such as noradrenergic or combined noradrenergic
and serotonergic mechanisms [18], require further investigation.
In summary, the structural neural correlates of depression show
high prognostic potential for treatment with the antidepressant
medication fluoxetine. However, the diagnostic accuracy with
structural neuroanatomy was more limited, while greater diag-
nostic potential may be found with functional neural correlates.
The present findings may provide an initial step towards
developing personalised clinical treatment options.
Materials and Methods
Participants
All participants provided written informed consent in accor-
dance with the guidelines of the Institute of Psychiatry and South
London and Maudsley (SLAM) NHS Trust Ethics (Research)
Committee. Patients were 37 right-handed individuals (mean age
41.9 years, SD 8.9; 28 women) meeting Diagnostic and Statistical
Manual of Mental Disorder-IV (DSM-IV) criteria [29] for major
depression by Structured Clinical Interview for DSM-IV [30], in
an acute episode of moderate severity, having a minimum score of
18 on the 17-item Hamilton Rating Scale for Depression (HRSD)
(mean HRSD 20.7, SD 2.2) [31]. Exclusion criteria were a history
of neurological trauma resulting in a loss of consciousness, a
current neurological disorder, history of diabetes or other medical
disorder, other Axis I disorder including an anxiety disorder,
history of substance abuse within 2 months of study participation,
or an Axis II disorder. All patients were free of psychotropic
medication for a minimum of 4 weeks at recruitment (8 weeks for
fluoxetine) and patients in the CBT treatment group remained
medication-free throughout the treatment. Healthy controls were
37 right-handed individuals matched for age, gender and IQ
(mean age 42.2 years, SD 9.0; 28 women) with no history of a
psychiatric disorder, neurological disorder or head injury resulting
in a loss of consciousness, and an HRSD score#7 (mean HRSD
0.2, SD 0.6). There was no significant difference in age between
groups (paired t-test, t = 0.17, df = 36, p = 0.87) or verbal IQ:
patients 109.6, controls 114.1 (paired t-test, t = 1.16, df = 25,
p = 0.25). All participants were recruited by advertisement from
the local community, and all patients were outpatients. Some of
the patient group had participated in a treatment study of
depression with the antidepressant medication fluoxetine 20 mg
daily (18 depressed patients) [4] or with CBT (12 depressed
patients) [8], in which clinical remission was defined as a
HRSD#7 following 8 weeks of treatment with fluoxetine (9
patients achieved remission, 9 with residual symptoms) or 16
weeks with CBT (6 remission, 6 residual symptoms) (Table 1). The
remaining patients only participated in a single MRI scan and
declined the longitudinal treatment study.
Image Acquisition
Structural magnetic resonance imaging (MRI) data were acquired
as 3D spoiled gradient recalled (SPGR) T1-weighted scans on a 1.5
T GE NV/i Signa system (General Electric, Milwaukee, Wisconsin)
at the Maudsley Hospital, SLAM NHS Trust, London. The
acquisition parameters were: TE=8, TR=24 ms, flip angle= 30u,
field of view=25 cm625 cm, slice thickness= 1.3 mm, number of
slices= 124, image matrix= 25662566124.
Image Analysis
Voxel-based morphometry (VBM) was applied to the structural
MRI images using SPM5 (Wellcome Trust Centre for Neuroim-
aging, UCL, London, UK). The images were segmented into grey
Table 1. Demographic features.
Healthy Controls Depressed Patients Medication Treatment CBT Treatment
Remission Non-remission Remission Non-remission
Number of subjects 37 37 9 9 6 6
Mean Age (years) 42.8 (6.7) 43.2 (8.8) 44.2 (10.3) 44.1 (6.0) 41.2 (11.7) 42.7 (6.6)
Sex (m/f) 9/28 9/28 2/7 2/7 2/4 1/5
Verbal IQ 114.1 (13.0) 109.6 (17.1) 107.8 (13.0) 101.1 (13.2) 118.2 (16.4) 107.2 (24.4)
Baseline HRSD 0.2 (0.6) 20.6 (2.2) 20.2 (1.7) 22.0 (2.8) 20.7 (2.0) 20.8 (1.9)
Final HRSD 0.0 (0.0) 8.5 (4.8) 4.2 (1.5) 12.2 (4.4) 2.8 (2.8) 10.0 (5.7)
Remission was defined as a final HRSD#7 after 8 weeks of treatment with fluoxetine or 16 weeks of treatment with CBT, and Non-remission was a final HRSD.7; HRSD:
Hamilton Rating Scale for Depression; CBT: cognitive behavioural therapy.
doi:10.1371/journal.pone.0006353.t001
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matter (GM), white matter (WM) and cerebrospinal fluid and
imported into a rigidly aligned space [32]. GM segments were
then iteratively registered by non-linear warping to templates
generated from all images in each group by the Diffeomorphic
Anatomical Registration Through Exponentiated Lie algebra
(DARTEL) toolbox [33]. Modulation with additional scaling by
the Jacobian determinants of the nonlinear deformation was
applied to the normalized images [34–35] to preserve the overall
amount of each tissue class after normalisation. Images were
smoothed with a 6 mm full width at half maximum (FWHM)
Gaussian kernel. The outputs of this procedure were the
population templates of GM and the deformation parameters of
each individual to this template. The deformation parameters
were then used to generate the modulated and normalized GM
maps, which are in a standard space, and to conserve global GM
volumes. The input features for the subsequent analysis were the
smoothed modulated normalized GM images.
Given the very high dimensionality of the VBM output
(thousands of voxels, or features, for each subject, each one
corresponding to one dimension) and the expectation that only a
few of these features would be meaningful for prediction, we
applied a further feature selection step [36]. We used whole-brain
ANOVA filtering to select the areas of maximum group
differences between patients and controls. First the t-value and
degrees of freedom were estimated for each voxel in the training
set. Then the t-map was converted into a p-map, and voxels higher
than the threshold (uncorrected p=0.005) were masked out and
discarded for classification purposes.
Support vector machine is a supervised, multivariate classifica-
tion method [37] with optimal empirical performance in many
classification settings [38] that has previously been utilized in
neuroimaging research [2–3,7,9]. Supervised refers to the training
step in which the differences between the groups to be classified
are learned. With structural MRI data, individual images are
treated as points located in a high dimensional space, defined by
the GM voxel values of the ANOVA-thresholded maps. A linear
decision boundary in this high dimensional space is defined by a
hyperplane, and SVM finds the hyperplane that maximizes the
margin between two training groups, i.e. the separation between
the training subjects that are most ambiguous and difficult to
classify. In the SVM classification, the whole multivariate VBM
pattern over the set of thresholded areas jointly generated the
significant classification results, and the significance of such results
therefore refers to the whole pattern.
To examine whether the SVM classifier could be expected to
predict diagnosis or prognosis in new patients, we trained the
model with leave-one-out cross validation. For each cross
validation iteration, the data were partitioned into training and
test sets. A different participant from each group was excluded at
each iteration, and the SVM classifier was trained on the data
from the other subjects, after the ANOVA feature selection step.
This classifier was then used to predict the status of the test
participant based on their structural scan alone. The process was
repeated leaving each participant out once, allowing an accuracy
measure to be determined based on the number of test examples
correctly classified. Statistical significance of the overall classifica-
tion accuracy was determined by permutation testing, by repeating
the cross-validation procedure 300 times with a different random
permutation of the training group labels. The SVM classifier was
implemented using freely available software (LIBSVM, http://
www.csie.ntu.edu.tw/,cjlin/libsvm).
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